Dr. Anuja Jhingran, MD

Dr. Jhingran practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Jhingran's NPI, 1437244522, was assigned on October 4, 2006. Dr. Jhingran graduated from Texas Tech University Health Sciences Center School of Medicine in 1988. Dr. Jhingran holds Texas license H6316.

Dr. Jhingran's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Jhingran's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jhingran practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Jhingran's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Jhingran is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Jhingran's licenses on file in 3 states: Texas, Florida and Oklahoma.

Dmand AI lists cervical cancer radiation and uterine cancer radiation among the conditions Dr. Jhingran treats.

CMS data shows 561 Medicare services from Dr. Jhingran across 13 procedure codes in 2024, for 93 Medicare patients. Medicare paid $42,227 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 93 Medicare patients who saw Dr. Jhingran in 2024. The largest group is 65 to 74, with 50 patients. 74% of them have cancer, and 69% have high blood pressure. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jhingran's median patient age at 69, with 99% women.

In 2024, Dr. Jhingran wrote 45 Medicare Part D claims for 21 patients. 100% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $146 in total drug cost. In 2022, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Jhingran for performance year 2024, reported as part of a group. Dr. Jhingran accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 160 papers to Dr. Jhingran, published from 2005 to 2025. 2022 was the busiest year, with 15. The most frequent topics are Uterine Cervical Neoplasms, Endometrial Neoplasms and Brachytherapy. Dr. Jhingran has published most often in Int J Gynecol Cancer. Dr. Jhingran's most frequent co-authors are Ann H. Klopp, MD, PhD, Patricia J. Eifel, MD and Lilie L. Lin, MD.

Dmand AI links Dr. Jhingran to 5 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Uterine Cervical Neoplasms, Uterine Cervical Diseases and Cystadenocarcinoma. M.D. Anderson Cancer Center sponsors the most, 2.

CMS Open Payments shows 4 general payments to Dr. Jhingran from 3 drug and device companies from 2017 to 2023. Consulting fees make up the largest share, 90% of the total. Genentech, Inc. paid the most, $1,980.

Dmand AI lists 4 awards for Dr. Jhingran, most recently America's Top Doctors in 2014.

Dr. Jhingran graduated from Texas Tech University Health Sciences Center School of Medicine in 1988.

Dr. Jhingran is in network with 9 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.